Analysts Set Biodesix, Inc. (NASDAQ:BDSX) Target Price at $32.50

Shares of Biodesix, Inc. (NASDAQ:BDSX) have received an average recommendation of “Moderate Buy” from the six research firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $32.50.

A number of research firms recently commented on BDSX. Wall Street Zen raised shares of Biodesix to a “sell” rating in a research note on Saturday, September 13th. Canaccord Genuity Group set a $20.00 price objective on shares of Biodesix and gave the stock a “buy” rating in a research note on Friday, September 19th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biodesix in a research note on Wednesday, October 8th.

Biodesix Stock Performance

NASDAQ:BDSX opened at $7.60 on Friday. The firm has a market capitalization of $55.71 million, a PE ratio of -1.37 and a beta of 0.98. The stock’s fifty day moving average is $7.59 and its 200 day moving average is $7.37. Biodesix has a fifty-two week low of $3.44 and a fifty-two week high of $32.20. The company has a debt-to-equity ratio of 41.11, a quick ratio of 2.14 and a current ratio of 2.14.

Biodesix (NASDAQ:BDSX) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($1.16) EPS for the quarter, topping the consensus estimate of ($1.60) by $0.44. Biodesix had a negative net margin of 49.31% and a negative return on equity of 358.61%. The company had revenue of $21.77 million during the quarter, compared to analyst estimates of $20.98 million. Biodesix has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Biodesix will post -0.35 earnings per share for the current year.

Insiders Place Their Bets

In other Biodesix news, Director Jack W. Schuler bought 142,045 shares of Biodesix stock in a transaction on Friday, September 19th. The shares were acquired at an average price of $7.04 per share, for a total transaction of $999,996.80. Following the completion of the purchase, the director directly owned 1,380,745 shares in the company, valued at approximately $9,720,444.80. This trade represents a 11.47% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders acquired 334,836 shares of company stock valued at $2,611,362 and sold 293 shares valued at $2,461. 30.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Birchview Capital LP increased its stake in Biodesix by 2.8% in the 1st quarter. Birchview Capital LP now owns 5,736,113 shares of the company’s stock worth $3,586,000 after buying an additional 154,937 shares during the period. Monashee Investment Management LLC grew its stake in Biodesix by 15.7% in the 1st quarter. Monashee Investment Management LLC now owns 4,050,000 shares of the company’s stock worth $2,532,000 after acquiring an additional 549,121 shares in the last quarter. XTX Topco Ltd increased its position in shares of Biodesix by 99.4% during the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after acquiring an additional 102,494 shares during the period. Finally, Blair William & Co. IL raised its stake in shares of Biodesix by 33.3% during the first quarter. Blair William & Co. IL now owns 124,100 shares of the company’s stock valued at $78,000 after acquiring an additional 31,000 shares in the last quarter. 20.96% of the stock is currently owned by institutional investors.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.